Gigalab, a French biotechnology company, is positioning rapid diagnostic tests as a key component of national health sovereignty. The company develops point-of-care tests that can detect infectious diseases in minutes, aiming to reduce reliance on imported medical supplies.
Founded in 2020, Gigalab has focused on creating affordable, easy-to-use diagnostic tools for diseases such as COVID-19, influenza, and other respiratory infections. The company's strategy aligns with French government efforts to secure domestic production capacity for critical health technologies.
According to company statements, Gigalab's tests are designed for use in pharmacies, clinics, and remote areas, enabling faster clinical decisions. The firm has received funding from French public investment bank Bpifrance to scale up manufacturing.
Industry analysts note that the COVID-19 pandemic exposed vulnerabilities in global supply chains for diagnostics. Gigalab's approach could help France maintain stockpiles and respond more quickly to future health crises.
